EYPT - EyePoint Pharmaceuticals, Inc.
NEXT EARNINGS:
Mar 4, 2026
(in 7 days)
EPS Est: $-0.78
|
Rev Est: $1.0M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$37.50
DETAILS
HIGH:
$39.00
LOW:
$36.00
MEDIAN:
$37.50
CONSENSUS:
$37.50
UPSIDE:
119.94%
Market Cap:
1.41B
Volume:
1,140,564
Avg Volume:
1,264,876
52 Week Range:
3.91-19.11
Sector:
Healthcare
Industry:
Biotechnology
Beta:
1.79
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
165
IPO Date:
2005-01-27
EPS (TTM):
-2.32
P/E Ratio:
-3.20
Revenue (TTM):
43.27M
Total Assets:
418.46M
Total Debt:
21.86M
Cash & Equiv:
99.70M
Rev Growth (5Y):
16.3%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-35.4%
Debt/Equity:
0.06
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-05 | $-0.85 | $-0.77 | -10.4% | $966000 | $1.0M | -4.0% |
| 2025-08-06 | $-0.85 | $-0.67 | -26.9% | $5.3M | $4.1M | +29.2% |
| 2025-05-07 | $-0.65 | $-0.65 | 0.0% | $24.5M | $6.8M | +258.4% |
| 2025-03-05 | $-0.64 | $-0.54 | -18.5% | $11.6M | $8.2M | +41.5% |
| 2024-11-07 | $-0.54 | $-0.48 | -12.5% | $10.5M | $10.6M | -0.3% |
| 2024-08-07 | $-0.58 | $-0.55 | -5.5% | $9.5M | $9.6M | -1.2% |
| 2024-05-08 | $-0.55 | $-0.34 | -61.8% | $11.7M | $10.0M | +17.1% |
| 2024-03-07 | $-0.33 | $-0.60 | +45.0% | $14.0M | $8.9M | +57.6% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.27M | 46.02M | 41.40M | 36.94M | 34.44M | 20.36M | 2.96M | 7.54M | 1.62M | 26.57M | 3.47M | 2.14M |
| Net Income | (130.87M) | (70.80M) | (102.25M) | (58.42M) | (45.39M) | (56.79M) | (53.17M) | (18.48M) | (21.55M) | 6.35M | (13.36M) | (11.90M) |
| EPS | -2.32 | -1.82 | -2.74 | -2.03 | -3.54 | -6.04 | -11.50 | -5.23 | -6.81 | 2.16 | -4.87 | -5.16 |
| Total Assets | 418.46M | 355.18M | 180.36M | 263.37M | 91.72M | 72.97M | 71.67M | 18.68M | 31.62M | 32.37M | 22.67M | 16.25M |
| Total Debt | 21.86M | 4.91M | 46.35M | 39.20M | 40.99M | 50.60M | 17.31M | 17.31M | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 99.70M | 281.26M | 95.63M | 178.59M | 44.91M | 22.21M | 38.78M | 16.90M | 15.31M | 19.12M | 15.33M | 6.90M |
| Operating Cash Flow | (126.23M) | 1.88M | (65.00M) | (50.10M) | (14.44M) | (56.70M) | (21.91M) | (20.49M) | (16.32M) | 10.30M | (10.67M) | (8.74M) |
| Free Cash Flow | (130.28M) | (1.61M) | (67.16M) | (50.25M) | (14.80M) | (56.91M) | (22.02M) | (20.64M) | (16.43M) | 10.14M | (10.92M) | (8.81M) |
| FCF per Share | -2.31 | -0.04 | -1.80 | -1.75 | -1.15 | -5.46 | -4.76 | -5.84 | -5.20 | 3.45 | -3.98 | -3.82 |
| Book Value | 336.50M | 266.32M | 96.37M | 184.38M | 18.54M | 8.33M | 11.69M | 13.34M | 20.88M | 23.37M | 14.92M | 7.70M |
| Cash & ST Investments | 370.91M | 331.05M | 144.56M | 211.56M | 44.91M | 22.21M | 38.78M | 16.90M | 28.99M | 28.54M | 18.28M | 10.27M |
| ROC Equity | -0.39 | -0.27 | -1.06 | -0.32 | -2.45 | -6.82 | -4.55 | -1.39 | -1.03 | 0.27 | -0.89 | -1.55 |